Compare Barrick Gold Corp (B) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barrick Gold Corp vs Citius Pharmaceuticals Inc — how do they compare? Barrick Gold Corp trades at $40.29 (market cap $68.49B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M). The key difference: Barrick Gold Corp is far larger — about 3656.7× Citius Pharmaceuticals Inc's market cap, and Barrick Gold Corp pays a 1.71% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| B | CTXR | |
|---|---|---|
Market Cap | $68.49B | $18.73M |
Sector | Basic Materials | Health |
52-Week High | $52.97 | $1.82 |
52-Week Low | $22.83 | $0.48 |
Enterprise Value | $66.08B | $14.95M |
Dividend Yield | 1.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Barrick Mining (B) trades at $43.69, up 5.49% in 24 hours, with a bullish technical outlook and strong fundamentals. Recent earnings beats, a $1.95 billion settlement with Newmont, and a robust cash flow trend highlight operational strength. The stock is near its consensus price target of $50.17, supported by a 66.67% analyst buy rating.
The outlook is positive due to earnings growth, favorable valuations, and strategic initiatives like the North American IPO. Risks include gold price volatility and execution of expansion plans. Upside potential exists if the company maintains its earnings momentum and capitalizes on gold market trends.
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
